Search 

AnGes is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of gene-based medicines including gene therapy, oligonucleotide drugs and DNA vaccines.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.

Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.

MSL Pharma is an early-stage pharma company that performs ideation, analysis and identification of the underlying pathological pathways to determine how to treat diseases. The Company holds exclusive licenses from the Hebrew University & Ben-Gurion University of the Negev. There are data, patents and publications concerning the technologies.

As an early-stage company, in order to reduce overhead costs, we effectively act as the project manager – we plan the assays and subcontract the early development stages to university labs, and the later stages to CROs that specialize in the different fields. The Company monitors the results, determines next steps and fundraises for the next phases of development. We believe that working with leading experts at CROs is critical for success.

The Company has licenses for platform technologies which are progressing to several different projects; as such it is planning to out-license at various stages of development.

Synthesis of cyclic peptides which are peptidomimetics
MSL Pharma has the capability to identify “active regions” of proteins and peptides, to isolate them and to turn them into cyclic peptides which are selective for the desired receptors and stable, thereby preventing off-target activation and adverse effects (see Asset, Table 1).

Drug delivery systems for peptides and other molecules
MSL Pharma has two technologies for drug delivery (see Mode of Delivery, Table 1) that achieve unprecedented bioavailability:
1. Lipophilic prodrug charge masking (LPCM) technology for the oral delivery of peptides. This technology makes a chemical modification in a peptide to be converted to oral delivery, to produce a prodrug of this peptide. This causes it to be absorbed through the intestinal cell and once the prodrug enters the blood stream, it converts back to the original peptide. Typically, the Pgp Efflux system limits the prodrug absorption; we have overcome this with an approved self-assembling PNL (pro-nano liposphere) encapsulation system, itself a self-nanoemulsifying drug delivery system (SNEDDS), which increases prodrug solubility and inhibits the Pgp Efflux system.

2. A novel nanoparticle formulation called AmyloLipid Nanovesicles which is constructed of natural materials and therefore safe ,biodegradable and has an advantage for the delivery of peptides. This technology is used also for the delivery of other molecules, can be used for nose-to-brain, sublingual, transdermal and probably also oral delivery, and can be applied to our assets (Table 1) or existing assets (Table 2).

A novel smart multi-armed linker for targeted drug delivery
Our linker can be used for peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs) and nanoparticle-drug conjugates (NDCs). Our linker releases the payload (chemotherapeutic drug or fluorescent) only in the tumor cells and can bind up to three payloads (see Table 3). We have demonstrated that using two or three different drug payloads kills the tumor cells more potently and with less drug resistance developing.

Discovery of novel peptides for peptide-drug conjugates
We have technologies to synthesize novel peptides which will bind to receptors overexpressed in certain tumors so that we will be able to use them for synthesizing peptide-drug conjugates (PDCs) to diagnose and treat different tumors. We already have at our disposal peptides that bind to the five different somatostatin receptors (overexpressed in pancreatic, gallbladder, breast, ovary, prostate, melanoma, lymphoma, glioblastoma, colon and non-small-cell lung tumors) and to certain integrin receptors (overexpressed in tumors such as breast, glioblastoma, leukemic cells). 

Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. Our lead asset is ready for clinical development in 2021 and expect to reach PoC in myocardial infarction within 3 years.

Selfit is a digital therapy startup focusing on the aging population and brain and heart conditions.
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.